Siemens Healthineers in the news

On October 9, 2026, Siemens Healthineers stock traded at EUR 38.78 with significantly low volume, its price closer to the 52-week low, and a P/E ratio of 19.55.

Siemens Healthineers stock saw a slight pre-market dip to EUR 38.50, ahead of its November 5 balance-sheet press conference.

Siemens Healthineers stock hovers around 39 Euros as the company balances new product momentum and share buybacks against persistent cost inflation and a cautious market outlook.

Siemens Healthineers' MRI system received ENERGY STAR certification, while the company faces market skepticism regarding profitability and is preparing for its Q4 and full 2026 fiscal year earnings report on November 5, 2026.

Siemens Healthineers is expanding its product pipeline in lab diagnostics and radiation oncology with new partnerships and platforms, while facing mixed analyst opinions and a patent dispute.

Siemens Healthineers is launching new diagnostic and radiotherapy products, with upcoming Q4 earnings critical for investors evaluating the company's ability to translate innovation into profitable revenue amid market skepticism about margins.

Siemens Healthineers' stock is below its yearly high, with Q3 2026 revenue up 1.8%, while full-year revenue guidance was lowered due to Diagnostics pressure, despite increased EPS guidance and ongoing share buybacks.

Siemens Healthineers introduces new radiotherapy and diagnostic products and partnerships while facing a patent lawsuit and stock decline, with investors awaiting Q4 results to assess future profitability.

Siemens Healthineers is pushing AI and new product rollouts while facing investor scrutiny over profitability and valuation ahead of its Q4 earnings report on November 5, 2026.

Siemens Healthineers' stock fell 0.05% pre-market on October 8, 2026, and the company is conducting a share buyback program of up to EUR 230 million, with 3,424,346 shares acquired by October 4.

Siemens Healthineers supports its international staff and overall employee well-being through dedicated networks, surveys, and mental health initiatives, contributing to high employee retention and attraction rates.

Deutsche Bank maintained a 'Hold' rating on Siemens Healthineers stock with a EUR 39.00 price target, citing concerns about weak profitability and the Diagnostics segment ahead of the company's fiscal fourth-quarter results.

Siemens Healthineers stock experienced a slight increase in pre-market trading and continued its share buyback program, repurchasing nearly 50,000 shares in the last week of September and early October 2026.

Siemens Healthineers is expanding its diagnostics and oncology portfolio through new alliances and product launches, aiming to stabilize its Diagnostics segment and drive future growth.

Siemens Healthineers appointed Guilherme Marques as the new managing director for Great Britain and Ireland, succeeding Ghada Trotabas.

Siemens Healthineers is highlighted as an investment opportunity due to its new, potentially revolutionary radiation therapy.

Siemens Healthineers is preparing to release Q4 results on November 5, 2026, with analysts divided on its profitability and stock performance, while the company continues operational advancements and a share buyback program.

Siemens Healthineers stock saw a modest rise, with recent financial results showing increased revenue and EPS, while future earnings and dividend predictions remain positive.

Siemens Healthineers stock traded stably at 38.09 EUR on XETRA, with positive Q3 2026 earnings and analyst predictions for increased dividends and a higher price target.

Siemens Healthineers stock rose by 0.5% to 38.25 EUR on October 8, 2026, following positive quarterly results with increased revenue and earnings per share.